Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabotegravir stearate
- Development stage
- Phase 1
- Lead developer
- University of Nebraska Medical Center
- Modality
- Small Molecules
- Administration
- Intramuscular, Subcutaneous
01
Overview
VH4367310 (also known as VH-310 or XVIR-110) is an investigational, ultra-long-acting prodrug of the integrase strand transfer inhibitor (INSTI) cabotegravir. Originally developed by researchers at the University of Nebraska Medical Center (UNMC) and licensed to Exavir Therapeutics, the compound was subsequently out-licensed to ViiV Healthcare for clinical development. VH4367310 is formulated as an aqueous nanocrystalline suspension of cabotegravir stearate (M2CAB), a lipophilic 18-carbon ester prodrug. Following intramuscular or subcutaneous injection, the nanocrystals slowly dissolve and undergo esterase-catalyzed hydrolysis to release active cabotegravir, creating a sustained drug depot. This mechanism provides an exceptionally long half-life, supporting a dosing interval of every six months or longer. VH4367310 is currently in Phase 1 clinical development for the treatment and prevention (pre-exposure prophylaxis, or PrEP) of HIV-1 infection.
- Other names
- M2CABM-2CABM 2CABcabotegravir stearoylatecabotegravir stearoylate prodrug
02
Targets
Integrase allosteric pocket (HIV)
Beyond the preview
Go deeper on cabotegravir stearate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabotegravir stearate.